Tumor lysis syndrome

https://doi.org/10.1016/S0037-1963(01)90037-XGet rights and content

Abstract

Tumor lysis syndrome (TLS) is a constellation of metabolic disturbances observed in tumors with high cell turnover. It is associated with significant morbidity and mortality. TLS is characterized by the increased release of intracellular contents (uric acid, potassium, phosphorus) into the extracellular compartment, which can overwhelm the body's capacity for clearance. TLS is usually caused by response to chemotherapy; however, it may also occur spontaneously. Because uric acid, potassium, and phosphorus are excreted primarily by the kidneys, TLS can lead to hyperuricemia, hyperkalemia, and hyperphosphatemia with accompanying renal compromise. The pathophysiology of TLS-associated acute renal failure is probably multifactorial. Potential etiologies include intravascular volume depletion, urinary precipitation of nucleic acid metabolites and calcium phosphate, and malignancy-associated nephrotoxins. Despite prophylactic therapy with allopurinol and volume repletion, patients may still develop TLS with acute renal failure. While reducing the risk of uric acid precipitation, allopurinol and alkalinization increase the risk of xanthine and calcium phosphate crystals, respectively. Aggressive hydration might lead to volume overload, specifically in older patients. Novel approaches in the management of TLS include the use of urate oxidase, which can provide effective treatment with an acceptable safety profile.

References (25)

  • DR Fleming et al.

    Acute tumor lysis syndrome in hematologic malignancies

    Leuk Lymphoma

    (1992)
  • CD Flombaum

    Metabolic emergencies in the cancer patient

  • Cited by (125)

    • Tumor Lysis Syndrome

      2021, Advances in Chronic Kidney Disease
    • Elevated uric acid and adenosine triphosphate concentrations in bronchoalveolar lavage fluid of eosinophilic pneumonia

      2017, Allergology International
      Citation Excerpt :

      DAMPs, induced by tissue injury, interact predominantly with host pattern recognition receptors and induce inflammation and immune responses.11–13 Among known DAMPs, the role of UA in the development of immune responses has been highlighted.16,22–28 UA is a major endogenous danger signal released from injured cells, and large concentrations of UA can be produced in vivo.22,23

    • Challenges and opportunities for monoclonal antibody therapy in veterinary oncology

      2016, Veterinary Journal
      Citation Excerpt :

      The second type of possible reactions is dependent on antibody activity. One possible effect of mAbs is the formation of tumour lysis syndrome, where the release of intracellular contents from the tumour after being targeted by treatment leads to metabolic disorders, such as hyperkalaemia, hyperphosphataemia and hypocalcaemia (Jeha, 2001; Gilbert and Wright, 2015). Undesired antibody activity has led to life threatening situations in the famous case of the CD28 superagonist antibody TGN1412, used with the goal of stimulating immune responses.

    • Tumor Lysis Syndrome

      2013, Renal Disease in Cancer Patients
    View all citing articles on Scopus
    1

    Dr. Jeha receives grant and research support from Sanofi-Synthélabo. She is also a consultant for and a member of the Sanofi-Synthélabo Speakers Bureau.

    View full text